NEW YORK, September 17, 2012 - Marketsareopen, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Savient Pharmaceuticals, Cell Therapeutics, Complete Genomics, Threshold Pharmaceuticals.

Savient Pharmaceuticals, Inc.(NASDAQ:SVNT) shares climbed 11.41% to $2.05 in the morning hour. The 52 week trading range for the company is $0.48 - $4.75. The shares of the company plunged 49% in the last one year. On September 4, 2012, SVNT received a letter from The NASDAQ Stock Market notifying it that it had regained full compliance with the NASDAQ Global Market's minimum bid price continued listing requirement as a result of the closing bid price of its common stock having been at or above the minimum requirement of $1.00 per share for at least 10 consecutive trading days.

Will SVNT Continue To Move Higher? Find Out Here http://marketsareopen.com/reports/index.php?company=SVNT

Cell Therapeutics Inc(NASDAQ:CTIC) stock gained 3.82% to $2.99 in the early hour. The company last week said that it has launched its recently approved oncology drug Pixuvri in the EU. Pixuvri was approved by EU regulators in May for the treatment of aggressive B-cell non-Hodgkin lymphoma, or NHL. Approximately 37,000 new cases of aggressive B-cell NHL are diagnosed in the EU every year.

The 52 week trading range for the company is $1.77 - $8.25. The shares of the company plunged 50% in the last one year.

How Should Investors Trade CTIC After The Recent Gain? Find Out Here http://marketsareopen.com/reports/index.php?company=CTIC

Complete Genomics, Inc.(NASDAQ:GNOM) stock climbed 14.24% to $3.05 after GNOM and and BGI-Shenzhen announced that they have entered into a definitive merger agreement. Under the agreement, a wholly-owned U.S. subsidiary of BGI-Shenzhen will launch a tender offer to buy all outstanding shares of common stock of Complete Genomics for $3.15 per share in cash, without interest.

Get Free Trend Analysis On GNOM Here http://marketsareopen.com/reports/index.php?company=GNOM

Threshold Pharmaceuticals, Inc.(NASDAQ:THLD) shares plummeted 18.92% to $7.07 after the company’s experimental pancreatic cancer drug didn’t significantly improve patients’ overall chance of survival. Patients treated with Threshold’s TH-302 plus chemotherapy had a median survival of 9.2 months compared with 6.9 months for those treated with only chemotherapy in the second of what are typically three phases of clinical studies needed for regulatory approval.

Will THLD Recover After The Recent Slump? Find Out Here http://marketsareopen.com/reports/index.php?company=THLD

About Marketsareopen
Marketsareopen’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Marketsareopen’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Marketsareopen.com.

Disclaimer:

The assembled information disseminated by marketsareopen.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. marketsareopen.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.

Contacts:
Marketsareopen
1419 Westwood Blvd Los Angeles, CA
90024-4911
staff@TheMarketsAreOpen.com
www.marketsareopen.com